Lexaria Bioscience Corp.

LEXX • Biotechnology

Movimiento fuerte

LEXX+14.85%

vs. cierre anterior $12.32

$14.15

▲ +1.83 (+14.85%)

Precio actual

ResultadosÚltimo reporte: 28 feb 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$345.88M

Crecimiento

-6.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.04Liquidez saludable · 2.32Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 28 feb 2026, 12:00 a.m. UTCÚltima actualización de earnings: 13 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$14.15

Change14.85%

Shares Out24.44M

Market Cap$345.88M

Enterprise Value$340.61M

52W Range0.46 - 1.55

Beta0.34

P/E-36.29

P/S939.89

P/B52.39

P/FCF-36.72

EV/Sales925.57

Price$14.15

Change14.85%

Shares Out24.44M

Market Cap$345.88M

Enterprise Value$340.61M

52W Range0.46 - 1.55

Beta0.34

P/E-36.29

P/S939.89

P/B52.39

P/FCF-36.72

EV/Sales925.57

EV/EBITDA-36.33

EV/FCF-36.16

Earnings Yield-2.76%

FCF Yield-2.72%

Dividend Yield0.00%

Gross Margin99.61%

Oper. Margin-16.83%

Profit Margin-16.86%

Debt/Eq0.04

Current Ratio2.32

Quick Ratio2.32

Revenue 5Y-5.99%

Target$1.50

Target Upside-89.40%

Target Median$1.50

Target Range1.50 - 1.50

Volume50.64K

Avg Volume121.12K

EPS Surprise0.04

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

40/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.04Liquidez saludable · 2.32Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

LEXX

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-15

Bajo

$1.50

Promedio

$1.50

Mediana

$1.50

Alto

$1.50

Resumen de la compañía

IPO: 1/12/2021

Industria: Biotechnology

P/B i: 52.39

Deuda / Patrimonio i: 0.04

Margen operativo: -1683.01%

Margen neto: -1686.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.04

Ratio corriente: 2.32

Ratio rápido: 2.32

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

BUNKA CHRISTOPHER

Transacción: 03/17/2026

VENTA

Cambio

-100,000

Precio

Not reported

Presentación

03/18/2026

Tipo

VENTA

BUNKA CHRISTOPHER

Transacción: 07/30/2025

COMPRA

Cambio

+11,900

Precio

$0.91

Presentación

07/30/2025

Tipo

COMPRA

CHRISTOPHER RICHARD

Transacción: 07/29/2025

COMPRA

Cambio

+15,000

Precio

$0.91

Presentación

07/30/2025

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
BUNKA CHRISTOPHER	VENTA	-100,000	Not reported	03/17/2026	03/18/2026
BUNKA CHRISTOPHER	COMPRA	+11,900	$0.91	07/30/2025	07/30/2025
CHRISTOPHER RICHARD	COMPRA	+15,000	$0.91	07/29/2025	07/30/2025
Carle Vanessa	COMPRA	+750	$0.91	07/29/2025	07/30/2025
DOCHERTY JOHN MARTIN	COMPRA	+5,376	$0.93	07/29/2025	07/30/2025
McKechnie William Edward	COMPRA	+5,000	$0.91	07/29/2025	07/30/2025
BUNKA CHRISTOPHER	COMPRA	+15,600	$0.92	07/29/2025	07/30/2025
REESE ALBERT L JR	COMPRA	+11,000	$1.04	05/15/2025	05/16/2025
Baxter Nicholas W	COMPRA	+11,000	$1.04	05/15/2025	05/16/2025
Bhullar Baljinder	COMPRA	+11,000	$1.04	05/15/2025	05/16/2025
Shankman Michael Elliot	COMPRA	+50,000	$1.04	05/15/2025	05/16/2025
DOCHERTY JOHN MARTIN	COMPRA	+150,000	$1.04	05/15/2025	05/16/2025
Carle Vanessa	COMPRA	+15,000	$1.04	05/15/2025	05/16/2025
BUNKA CHRISTOPHER	COMPRA	+11,000	$1.04	05/15/2025	05/16/2025
CHRISTOPHER RICHARD	COMPRA	+150,000	$1.04	05/15/2025	05/16/2025
Bhullar Baljinder	OTRO	0	Not reported	01/14/2025	01/16/2025
BUNKA CHRISTOPHER	COMPRA	+100,000	Not reported	01/07/2025	01/10/2025
CHRISTOPHER RICHARD	COMPRA	+27,172	$2.47	12/03/2024	12/03/2024
CHRISTOPHER RICHARD	COMPRA	+22,828	$2.24	12/02/2024	12/03/2024
Shankman Michael Elliot	OTRO	+50,000	$3.17	02/28/2025	10/02/2024

Sobre la compañía

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

Fuente - Link

Competidores

ALLR BCTX CASI CING CLSD CRIS ENTO HOTH LIXT PCSA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kelowna, British Columbia – September 4, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 th through September 16 th, 2026 in New York City. Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.

TheNewswire

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

TheNewswire

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Accesswire

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECHTM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.

Accesswire

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.

Benzinga

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-13	-0.1	-0.06	0.04
2026-01-13	-0.13	-0.07	0.06
2025-11-26	-0.16	-0.13	0.03
2025-07-14	-0.15	-0.21	-0.06
2025-04-14	-0.16	-0.15	0.01
2025-01-10	-0.12	-0.16	-0.04
2024-11-26	-0.11	-0.15	-0.04
2024-07-12	-0.1	-0.13	-0.03
2024-04-09	-0.1	-0.06	0.04
2024-01-12	-0.11	-0.13	-0.02
2023-11-21	-0.17	-0.12	0.05
2023-07-14	-0.25	-0.37	-0.12